Overview
The CDSCO under the Ministry of Health and Family Welfare has given marketing authorisation to Qdenga®. This is the first dengue vaccine approved for use in India, marking a major step in the country’s fight against dengue.
Key Developments
- Approval granted on 21 July 2026 after evaluation of quality, safety and efficacy as per the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945.
- Vaccine indicated for individuals aged 4–60 years with a two‑dose schedule (0 and 3 months).
- Manufactured by Takeda GmbH, Germany and imported by Takeda Biopharmaceuticals India Pvt. Ltd.
- Already approved in 42 countries and has WHO prequalification.
- More than 24 million doses distributed worldwide with a favourable post‑marketing safety profile.
Important Facts
The vaccine is produced in Vero cells. It contains genetically modified organisms (GMOs) and is supplied as a freeze‑dried powder for subcutaneous injection. Clinical data come from a global programme covering eight countries, including a pivotal Phase III clinical trial conducted in India.
Exam Relevance
Understanding this approval helps aspirants answer questions on:
- India’s regulatory framework for medicines (GS3: Health, Governance).
- Public‑health strategies against vector‑borne diseases, complementing the National Vector Borne Disease Control Programme.
- International cooperation in health, illustrated by WHO prequalification and multi‑country clinical trials (GS1: International Relations).
- Biotechnological advances such as recombinant DNA technology and GMO use in vaccines (GS3: Health, Science & Technology).
Way Forward
To maximise impact, the government should:
- Integrate Qdenga® into the existing dengue control strategy, ensuring cold‑chain logistics and equitable distribution.
- Strengthen surveillance to monitor vaccine‑derived immunity and any adverse events.
- Promote public awareness about the vaccine’s schedule and safety to improve uptake.
- Encourage further research on dengue therapeutics and vector control, maintaining a multi‑pronged approach.
With coordinated effort, the vaccine can reduce dengue incidence, lower healthcare costs and contribute to India’s broader goal of improving public health outcomes.